SCHEMBL5775341

SCHEMBL5775341

CC(C)c1nnc2ccc(-c3ocnc3-c3cccc(F)c3)cn12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772729 0.88 MAPK14 (1.00) MAPK14
SCHEMBL40860 0.88 MAPK14 (1.00) MAPK14
SCHEMBL5774189 0.87 MAPK14 (1.00) MAPK14
SCHEMBL4767945 0.87 MAPK14 (1.00) MAPK14
SCHEMBL5774497 0.86 MAPK14 (1.00) MAPK14
SCHEMBL5771520 0.85 MAPK14 (1.00) MAPK14
SCHEMBL4762399 0.84 MAPK14 (1.00) MAPK14
SCHEMBL4769791 0.84 MAPK14 (1.00) MAPK14
SCHEMBL4764009 0.84 MAPK14 (1.00) MAPK14
SCHEMBL4762527 0.84 MAPK14 (1.00) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370559-B1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PROD INC (US) 2006-04-19 EP disclosed
US-6696464-B2 POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK PFIZER INC 2004-02-24 US disclosed
EP-1370559-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS Pfizer Products Inc. (US) 2003-12-17 EP disclosed
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds PFIZER INC. 2003-05-22 US disclosed
WO-2002072579-A1 TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS PFIZER PRODUCTS INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096838-A1 Novel triazolo-pyridines anti-inflammatory compounds MAPK1, CNKSR1, JAK1 MAPK14 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.